Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.12659/AJCR.932963 http://hdl.handle.net/11449/229596 |
Resumo: | Background: Challenging differential diagnosis Adalimumab is a biological anti-tumor necrosis factor (TNF) agent which induces and maintains remission in patients with moderate-to-severe Crohn disease (CD). An adverse effect of its use is reactivation of latent in-fections, such as tuberculosis (TB). TB is caused by Mycobacterium tuberculosis and continues to be an impor-tant public health problem in some developing countries, such as Brazil. The present report describes the case of a patient with CD who developed pulmonary TB while receiving adalimumab therapy. A 38-year-old penitentiary worker presented with colonic CD that was intolerant to azathioprine and was started on adalimumab. After 3 months, he experienced coughing, fever, and weight loss, and was diagnosed with pulmonary TB. A chest X-ray and tuberculin skin test performed before he started taking adalimumab were negative for latent TB. The patient was treated for 9 months to cure his infection. The use of adalimumab was suspended while the TB was investigated and he took mesalazine to achieve clinical and endoscopic remission of CD. Adequate screening and chemoprophylaxis for latent TB are indicated in patients at high risk of infection. In patients with inflammatory bowel disease, after anti-TNF therapy is started, strict monitoring is required so that opportunistic infections can be detected early and morbidity and mortality reduced in this population. |
id |
UNSP_6fed838765374a5dd92c1dc0847931d4 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/229596 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case reportAdalimumabCrohn DiseaseInflammatory Bowel DiseasesLatent TuberculosisBackground: Challenging differential diagnosis Adalimumab is a biological anti-tumor necrosis factor (TNF) agent which induces and maintains remission in patients with moderate-to-severe Crohn disease (CD). An adverse effect of its use is reactivation of latent in-fections, such as tuberculosis (TB). TB is caused by Mycobacterium tuberculosis and continues to be an impor-tant public health problem in some developing countries, such as Brazil. The present report describes the case of a patient with CD who developed pulmonary TB while receiving adalimumab therapy. A 38-year-old penitentiary worker presented with colonic CD that was intolerant to azathioprine and was started on adalimumab. After 3 months, he experienced coughing, fever, and weight loss, and was diagnosed with pulmonary TB. A chest X-ray and tuberculin skin test performed before he started taking adalimumab were negative for latent TB. The patient was treated for 9 months to cure his infection. The use of adalimumab was suspended while the TB was investigated and he took mesalazine to achieve clinical and endoscopic remission of CD. Adequate screening and chemoprophylaxis for latent TB are indicated in patients at high risk of infection. In patients with inflammatory bowel disease, after anti-TNF therapy is started, strict monitoring is required so that opportunistic infections can be detected early and morbidity and mortality reduced in this population.Department of Internal Medicine São Paulo State University (UNESP) Medical SchoolDepartment of Radiology São Paulo State University (UNESP) Medical SchoolDepartment of Surgery São Paulo State University (UNESP) Medical SchoolDepartment of Internal Medicine São Paulo State University (UNESP) Medical SchoolDepartment of Radiology São Paulo State University (UNESP) Medical SchoolDepartment of Surgery São Paulo State University (UNESP) Medical SchoolUniversidade Estadual Paulista (UNESP)da Silva, Douglas Inomata Cardoso [UNESP]Santos, Bruna Helena de Oliveira [UNESP]Renosto, Fernanda Lofiego [UNESP]Watanabe, Erika Mayumi [UNESP]Herrerias, Giédre Soares Prates [UNESP]Saad-Hossne, Rogerio [UNESP]Baima, Julio Pinheiro [UNESP]Sassaki, Ligia Yukie [UNESP]2022-04-29T08:33:21Z2022-04-29T08:33:21Z2021-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.12659/AJCR.932963American Journal of Case Reports, v. 22, n. 1, 2021.1941-5923http://hdl.handle.net/11449/22959610.12659/AJCR.9329632-s2.0-85115806846Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengAmerican Journal of Case Reportsinfo:eu-repo/semantics/openAccess2024-08-14T17:23:00Zoai:repositorio.unesp.br:11449/229596Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T17:23Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report |
title |
Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report |
spellingShingle |
Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report da Silva, Douglas Inomata Cardoso [UNESP] Adalimumab Crohn Disease Inflammatory Bowel Diseases Latent Tuberculosis |
title_short |
Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report |
title_full |
Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report |
title_fullStr |
Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report |
title_full_unstemmed |
Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report |
title_sort |
Pulmonary tuberculosis after therapy with anti-tumor necrosis factor (Tnf) for crohn disease: A case report |
author |
da Silva, Douglas Inomata Cardoso [UNESP] |
author_facet |
da Silva, Douglas Inomata Cardoso [UNESP] Santos, Bruna Helena de Oliveira [UNESP] Renosto, Fernanda Lofiego [UNESP] Watanabe, Erika Mayumi [UNESP] Herrerias, Giédre Soares Prates [UNESP] Saad-Hossne, Rogerio [UNESP] Baima, Julio Pinheiro [UNESP] Sassaki, Ligia Yukie [UNESP] |
author_role |
author |
author2 |
Santos, Bruna Helena de Oliveira [UNESP] Renosto, Fernanda Lofiego [UNESP] Watanabe, Erika Mayumi [UNESP] Herrerias, Giédre Soares Prates [UNESP] Saad-Hossne, Rogerio [UNESP] Baima, Julio Pinheiro [UNESP] Sassaki, Ligia Yukie [UNESP] |
author2_role |
author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (UNESP) |
dc.contributor.author.fl_str_mv |
da Silva, Douglas Inomata Cardoso [UNESP] Santos, Bruna Helena de Oliveira [UNESP] Renosto, Fernanda Lofiego [UNESP] Watanabe, Erika Mayumi [UNESP] Herrerias, Giédre Soares Prates [UNESP] Saad-Hossne, Rogerio [UNESP] Baima, Julio Pinheiro [UNESP] Sassaki, Ligia Yukie [UNESP] |
dc.subject.por.fl_str_mv |
Adalimumab Crohn Disease Inflammatory Bowel Diseases Latent Tuberculosis |
topic |
Adalimumab Crohn Disease Inflammatory Bowel Diseases Latent Tuberculosis |
description |
Background: Challenging differential diagnosis Adalimumab is a biological anti-tumor necrosis factor (TNF) agent which induces and maintains remission in patients with moderate-to-severe Crohn disease (CD). An adverse effect of its use is reactivation of latent in-fections, such as tuberculosis (TB). TB is caused by Mycobacterium tuberculosis and continues to be an impor-tant public health problem in some developing countries, such as Brazil. The present report describes the case of a patient with CD who developed pulmonary TB while receiving adalimumab therapy. A 38-year-old penitentiary worker presented with colonic CD that was intolerant to azathioprine and was started on adalimumab. After 3 months, he experienced coughing, fever, and weight loss, and was diagnosed with pulmonary TB. A chest X-ray and tuberculin skin test performed before he started taking adalimumab were negative for latent TB. The patient was treated for 9 months to cure his infection. The use of adalimumab was suspended while the TB was investigated and he took mesalazine to achieve clinical and endoscopic remission of CD. Adequate screening and chemoprophylaxis for latent TB are indicated in patients at high risk of infection. In patients with inflammatory bowel disease, after anti-TNF therapy is started, strict monitoring is required so that opportunistic infections can be detected early and morbidity and mortality reduced in this population. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-01-01 2022-04-29T08:33:21Z 2022-04-29T08:33:21Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.12659/AJCR.932963 American Journal of Case Reports, v. 22, n. 1, 2021. 1941-5923 http://hdl.handle.net/11449/229596 10.12659/AJCR.932963 2-s2.0-85115806846 |
url |
http://dx.doi.org/10.12659/AJCR.932963 http://hdl.handle.net/11449/229596 |
identifier_str_mv |
American Journal of Case Reports, v. 22, n. 1, 2021. 1941-5923 10.12659/AJCR.932963 2-s2.0-85115806846 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
American Journal of Case Reports |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128146395889664 |